Mass Tort brief
Pfizer Settlement Split and Rising MDL Thresholds
Pfizer sets a strict cutoff on birth control cancer claims, while courts tighten dental and preemption standards across growing MDL dockets.
Mass Tort
Pfizer settled 80% of Depo-Provera claims to curb trial exposure — leaving 1,280 excluded cases to face make-or-break general causation hearings alone.
BackgroundDepo-Provera is an injectable progestin contraceptive administered every three months to prevent pregnancy. Thousands of women filed personal injury lawsuits alleging long-term use of the high-dose synthetic hormone significantly elevates the risk of developing intracranial meningiomas.
- The settlement covers roughly 5,130 of the 6,412 federal lawsuits coordinated before Judge M. Casey Rodgers, leaving unverified claims behind to face active litigation.
- Approximately 1,280 lawsuits failed to satisfy strict retention dates and medical diagnosis criteria, forcing them into active federal discovery without settlement protection.
- Excluded cases must fulfill individualized threshold injury proofs before proceeding to upcoming hearings on general scientific causation, raising the risk of outright dismissals.
Mass Tort
With 12,000 cases pending, the hair relaxer MDL is narrowing to five bellwether trials — setting up a decisive 2027 showdown with cosmetic giants.
BackgroundChemical hair relaxers rely on endocrine-disrupting chemicals like phthalates to permanently straighten coarse hair. National Institutes of Health studies revealed that frequent long-term use of chemical relaxers doubled the risk of uterine cancer among regular users.
- Expert witness discovery for the five chosen bellwether lawsuits will conclude in December 2026 ahead of crucial Daubert scientific admissibility hearings.
- The primary federal docket encompasses 12,381 coordinated injury lawsuits filed against major cosmetic manufacturers, representing one of the largest active federal MDLs.
- The first federal jury bellwether trial is scheduled to begin in Chicago on September 7, 2027, setting the settlement valuation baseline.
Mass Tort
Stricter dental record verification is weeding out unprovable Suboxone claims — while the remaining 2,000 cases march toward a decisive March 2028 trial.
BackgroundSuboxone is a sublingual film combining buprenorphine and naloxone prescribed to treat opioid addiction. The FDA warned that the acidic sublingual formulation causes severe dental decay, oral infections, and total tooth loss even in patients with healthy dental histories.
- The court ordered plaintiffs in the 50-case records collection pool to provide certified dental documentation and prescription timelines, targeting unsubstantiated filings.
- Attorneys are preparing core bellwether selections in early 2027 to prepare for initial federal jury trials scheduled for March 2028, establishing settlement ranges.
- Plaintiffs allege Indivior failed to warn patients to rinse with water after sublingual film dissolution, leading to preventable and catastrophic enamel erosion across thousands of users.
Mass Tort
Mass Tort
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
